SCHEMBL6110

SCHEMBL6110

CS(=O)(=O)C(CCC(N)=O)c1ccc(OCc2cccc3cccnc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MMP1 P03956 1/20 0.42
FFAR1 O14842 2/20 0.40
PLG P00747 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
PARP10 Q53GL7 1/20 0.38
KMT2A Q03164 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
MEN1 O00255 1/20 0.37
MTNR1A P48039 2/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11898956 0.79 ADAM17 (0.50) ADAM17MMP2MMP9MMP1FFAR1
SCHEMBL11898794 0.78 ADAMTS4 (0.47) ADAM17KMT2AMEN1
SCHEMBL5798 0.78 CYP27B1 (0.46) ADAM17PARP10PDE4APDE4BPDE4C
SCHEMBL10690 0.77 CYSLTR1 (0.54) FFAR1
SCHEMBL11899995 0.75 PARP10 (0.48) PARP10KMT2AMEN1LMNAMAPT
SCHEMBL11944 0.74 MAPT (0.53) FFAR1KMT2ALMNAMAPTTSHR
SCHEMBL5861 0.74 FFAR1 (0.56) FFAR1MAPTTSHR
SCHEMBL6074 0.73 CA12 (0.46) MMP9LMNA
SCHEMBL6159 0.73 PDE4A (0.43) FFAR1PARP10PDE4APDE4BPDE4C
SCHEMBL12050 0.72 ACACB (0.43) FFAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-12-11 US disclosed
US-8853258-B2 C-linked hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-10-07 US disclosed
EP-2488489-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS Pfizer Inc. (US) 2012-08-22 EP disclosed
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents BROWN MATTHEW FRANK (US) 2012-08-09 US disclosed
WO-2011045703-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents HAX1, LPXN, AGXT ADAM17 508/4885MMP2 360/4885MMP9 740/4885
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents LCT, AGXT, PRXL2A ADAM17 364/4885MMP2 464/4885MMP9 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.